Ophthotech Corporation clinical trials

Acquired by Astellas Pharma Inc, Jul 11, 2023 · source ↗

The registry lists 13 studies whose lead sponsor is Ophthotech Corporation. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 10, 2025.

Studies

Recruiting first, then most recently updated. Showing 13 of 13. All Astellas Pharma Inc studies →

• ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)CompletedNCT03362190Phase 2

  Sponsor listed in the registry: Ophthotech Corporation · First submitted before Ophthotech Corporation became part of Astellas Pharma Inc

• A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)CompletedNCT02397954Phase 2

  Sponsor listed in the registry: Ophthotech Corporation · First submitted before Ophthotech Corporation became part of Astellas Pharma Inc

• ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular DegenerationCompletedNCT00709527Phase 1

  Sponsor listed in the registry: Ophthotech Corporation · First submitted before Ophthotech Corporation became part of Astellas Pharma Inc

• A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular DegenerationCompletedNCT00950638Phase 1

  Sponsor listed in the registry: Ophthotech Corporation · First submitted before Ophthotech Corporation became part of Astellas Pharma Inc

• A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® MonotherapyTerminatedNCT01940887Phase 3

  Sponsor listed in the registry: Ophthotech Corporation · First submitted before Ophthotech Corporation became part of Astellas Pharma Inc

• A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)TerminatedNCT02387957Phase 2

  Sponsor listed in the registry: Ophthotech Corporation · First submitted before Ophthotech Corporation became part of Astellas Pharma Inc

• A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® MonotherapyTerminatedNCT01940900Phase 3

  Sponsor listed in the registry: Ophthotech Corporation · First submitted before Ophthotech Corporation became part of Astellas Pharma Inc

• A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® MonotherapyTerminatedNCT01944839Phase 3

  Sponsor listed in the registry: Ophthotech Corporation · First submitted before Ophthotech Corporation became part of Astellas Pharma Inc

• A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular DegenerationCompletedNCT01089517Phase 2

  Sponsor listed in the registry: Ophthotech Corporation · First submitted before Ophthotech Corporation became part of Astellas Pharma Inc

• Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMDTerminatedNCT02214628Phase 2

  Sponsor listed in the registry: Ophthotech Corporation · First submitted before Ophthotech Corporation became part of Astellas Pharma Inc

• A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular DegenerationCompletedNCT00569140Phase 1

  Sponsor listed in the registry: Ophthotech Corporation · First submitted before Ophthotech Corporation became part of Astellas Pharma Inc

• ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)WithdrawnNCT03374670Phase 2

  Sponsor listed in the registry: Ophthotech Corporation · First submitted before Ophthotech Corporation became part of Astellas Pharma Inc

• A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular DegenerationCompletedNCT00782093Phase 1

  Sponsor listed in the registry: Ophthotech Corporation · First submitted before Ophthotech Corporation became part of Astellas Pharma Inc